Protara Therapeutics (TARA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Program Overviews and Strategic Focus

• Three late-stage programs span oncology and rare diseases, all with prior human data supporting de-risking.

• Oncology focus is on TARA-002 for NMIBC, with a registrational phase 2 study in BCG-unresponsive patients and plans for BCG-naive studies in 2025.

• Rare disease portfolio includes IV choline chloride for parenteral support (phase 3) and TARA-002 for lymphatic malformations (phase 2), both with orphan or rare pediatric designations.

• TARA-002 and its predecessor, OK-432, have extensive global clinical experience, supporting safety and efficacy claims.

• Strong financial position with $102.7 million in cash, providing runway into 2027, supported by recent public offering.

Key Clinical and Pipeline Updates

• Positive interim results for TARA-002 in NMIBC, with 72% six-month CRR and 100% durability from 3 to 6 months; favorable safety profile with no Grade 2 or higher treatment-related adverse events.

• ADVANCED-2 trial expanding into BCG-naïve, combination, and systemic priming dosing cohorts; interim data from 12-month evaluable patients expected mid-2025.

• STARBORN-1 Phase 2 trial for TARA-002 in pediatric lymphatic malformations ongoing; large supporting dataset from a 550-patient study.

• IV Choline pivotal THRIVE-3 trial to initiate 1H'25, targeting choline-deficient parenteral support patients; FDA-cleared label for choline source with single study requirement.

• Manufacturing capacity for TARA-002 is robust, with 20M vial annual capacity, rapid batch completion, and no FDA Form 483s after inspection.

Product and Market Insights

• TARA-002 is a fully inactivated bacterial immunopotentiator, systemically dosable, and mechanistically distinct from BCG, with higher cytotoxicity and pro-inflammatory cytokine release.

• Administration of TARA-002 is rapid (15 minutes), nurse-driven, simpler and less burdensome than other NMIBC therapies, requiring no special handling or additional protocols.

• High-risk, high-grade NMIBC represents a $5–6B US addressable market, with over 65,000 annual patients and significant unmet need post-BCG failure.

• Addressable population includes 12,000–15,000 BCG-naive patients annually in the U.S. who cannot receive BCG.

• IV Choline addresses a rare disease population (~30,000–40,000 US patients), with 78% choline deficiency and associated liver, bone, and cognitive complications; choline replacement is guideline-recommended.